---
title: "AYJK released its 2024 annual performance, with a net profit attributable to the parent company of 40.5619 million yuan, a year-on-year decrease of 18.36%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/235864896.md"
description: "AYJK released its 2024 annual report, with operating revenue of 2.01 billion yuan, a year-on-year decrease of 7.54%; net profit attributable to the parent company was 40.5619 million yuan, a year-on-year decrease of 18.36%. The net profit after deducting non-recurring gains and losses was 32.5767 million yuan, a year-on-year increase of 19.35%. The basic earnings per share were 0.05 yuan"
datetime: "2025-04-14T11:58:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/235864896.md)
  - [en](https://longbridge.com/en/news/235864896.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/235864896.md)
generator: "portal-rs"
---

# AYJK released its 2024 annual performance, with a net profit attributable to the parent company of 40.5619 million yuan, a year-on-year decrease of 18.36%

According to the Zhitong Finance APP, AYJK (002172.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 2.01 billion yuan, a year-on-year decrease of 7.54%. The net profit attributable to shareholders of the listed company was 40.5619 million yuan, a year-on-year decrease of 18.36%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 32.5767 million yuan, a year-on-year increase of 19.35%. The basic earnings per share were 0.05 yuan

### Related Stocks

- [002172.CN](https://longbridge.com/en/quote/002172.CN.md)

## Related News & Research

- [TAL: Production exceeds targets and new royalty terms improve future economics](https://longbridge.com/en/news/298178519.md)
- [Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2](https://longbridge.com/en/news/298452346.md)
- [Resverlogix says new journal studies link apabetalone to lower heart-failure risk](https://longbridge.com/en/news/298584507.md)
- [Nootropics Depot Sponsors Future Nutra Innovation Summit](https://longbridge.com/en/news/298602187.md)
- [ZAWYA: Nigeria, APM Terminals advance Badagry port plan to boost West Africa trade](https://longbridge.com/en/news/298418254.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**